New Data on UCB, Inc. Cimzia® (certolizumab pegol) to be Presented at American College of Gastroenterology Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn’s Disease

ATLANTA--(BUSINESS WIRE)--UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, will present new data on Cimzia® (certolizumab pegol) at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place in Washington D.C. from October 28 to November 2.